Orbis Biosciences, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Orbis Biosciences, Inc. - Product Pipeline Review - 2016', provides an overview of the Orbis Biosciences, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Orbis Biosciences, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Orbis Biosciences, Inc. - The report provides overview of Orbis Biosciences, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Orbis Biosciences, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Orbis Biosciences, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Orbis Biosciences, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Orbis Biosciences, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Orbis Biosciences, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Orbis Biosciences, Inc. Snapshot 5 Orbis Biosciences, Inc. Overview 5 Key Information 5 Key Facts 5 Orbis Biosciences, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Orbis Biosciences, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Orbis Biosciences, Inc. - Pipeline Products Glance 11 Orbis Biosciences, Inc. - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 Orbis Biosciences, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Orbis Biosciences, Inc. - Drug Profiles 13 prednisone 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 betamethasone valerate ER 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 bupivacaine hydrochloride ER 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 etonogestrel ER 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 guaifenesin ER 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 meloxicam ER 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ORB-105 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ORB-203 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ritonavir 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 tramadol hydrochloride ER 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Orbis Biosciences, Inc. - Pipeline Analysis 23 Orbis Biosciences, Inc. - Pipeline Products by Target 23 Orbis Biosciences, Inc. - Pipeline Products by Route of Administration 24 Orbis Biosciences, Inc. - Pipeline Products by Molecule Type 25 Orbis Biosciences, Inc. - Pipeline Products by Mechanism of Action 26 Orbis Biosciences, Inc. - Locations And Subsidiaries 27 Head Office 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 28 Disclaimer 29
List of Tables
Orbis Biosciences, Inc., Key Information 5 Orbis Biosciences, Inc., Key Facts 5 Orbis Biosciences, Inc. - Pipeline by Indication, 2016 7 Orbis Biosciences, Inc. - Pipeline by Stage of Development, 2016 9 Orbis Biosciences, Inc. - Monotherapy Products in Pipeline, 2016 10 Orbis Biosciences, Inc. - Phase I, 2016 11 Orbis Biosciences, Inc. - Preclinical, 2016 12 Orbis Biosciences, Inc. - Pipeline by Target, 2016 23 Orbis Biosciences, Inc. - Pipeline by Route of Administration, 2016 24 Orbis Biosciences, Inc. - Pipeline by Molecule Type, 2016 25 Orbis Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2016 26
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.